SHA offering RSV protection for newborns

October 28, 2026

Media Release, Media Relations, Saskatchewan Health Authority

Key points from this story:

• SHA launches second RSV season
• Nirsevimab is long-acting monoclonal antibody
• Protects infants and young children
• Babies born Oct 1, 2026–Mar 31, 2027 eligible
• High-risk children up to two years eligible
• Some high-risk children may receive second dose

RSV is a common respiratory virus that can lead to serious illness in infants and young children.

All babies born in Saskatchewan between October 1, 2026, and March 31, 2027, are eligible to receive a single injection of nirsevimab before leaving their hospital or birthing site.

Unlike vaccines, which stimulate the body to produce its own immune response, nirsevimab is a monoclonal antibody that provides immediate protection against severe RSV disease. This is especially important for newborns whose immune systems generally do not produce their own antibodies for approximately the first three months of life.

High-risk infants and young children up to two years of age are also eligible to receive nirsevimab. Children who are considered high risk for severe Respiratory Syncytial Virus (RSV) may also receive a second dose, including children with cystic fibrosis, congenital heart disease, Down syndrome, respiratory conditions, weakened immune systems and certain neuromuscular disorders.